Small interfering RNA drugs in treatment of dyslipidemia
Автор: Atakhanova N.S.
Журнал: Экономика и социум @ekonomika-socium
Рубрика: Основной раздел
Статья в выпуске: 6-2 (97), 2022 года.
Бесплатный доступ
Inclisiran is the first example of an approved synthetic small interfering RNA (siRNA) drug for treating familial hypercholesterolemia. This review describes the scientific basis of RNA silencing, and critically evaluates the evidence relating to inclisiran, a small interfering RNA against proprotein convertase subtilisin kexin 9 (PCSK9).
Inclisiran, ldl cholesterol, dyslipidaemia, atherosclerosis
Короткий адрес: https://sciup.org/140299025
IDR: 140299025
Список литературы Small interfering RNA drugs in treatment of dyslipidemia
- Атаханова Н.С. Распространенности факторов риска сердечно сосудистих заболеваний среди женщин. // Экономика и социум. -2021. №7 (86). - C. 16-24.
- Penson P.E., Pirro M., Banach M. LDL-C: lower is better for longereven at low risk. BMC Med. 2020.18(1):320.
- Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al.Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016.388(10059):2532-61.
Статья научная
